Study Of Cold Cap Therapy For Prevention of Hairloss in Pediatric Patients Receiving Chemotherapy For Non-Malignant Indications and Solid Tumors

This study is testing whether a scalp cooling (cold cap) device can help prevent or reduce chemotherapy-induced hair loss in pediatric patients (age 7 and up) who are receiving chemotherapy for solid tumors or non-malignant conditions like sickle cell disease or aplastic anemia. Scalp cooling works by reducing blood flow to hair follicles during chemotherapy infusion, making them less exposed to the toxic drugs. It is already used in some adult cancer patients. Hair loss from chemotherapy can be deeply distressing, especially for young patients and their families. This study will help determine whether cold caps are safe and effective for this younger population, and for patients receiving chemotherapy for non-cancer conditions. You may be eligible if... - You are at least 7 years old - You are receiving chemotherapy likely to cause alopecia (such as cyclophosphamide, doxorubicin, paclitaxel, etoposide, or similar drugs) - You have been diagnosed with a solid tumor (non-brain) or a non-malignant condition (e.g., sickle cell disease or aplastic anemia) - Your head circumference is 50 cm or greater You may NOT be eligible if... - You are receiving chemotherapy for a blood cancer (hematologic malignancy) - You have a brain tumor, scalp tumor, or high risk of brain/scalp metastases - You have cold agglutinin disease or cold urticaria - You have an active scalp infection at enrollment - You have previously had a bad reaction to the Paxman scalp cooling device Talk to your doctor to see if this trial is right for you.